Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA, SGLT2i Jun 21 | 2021Jardiance HFrEF EC Approval; June 21-24 CHMP AgendaPurchase Blast
$599
Posted in: Basal Insulin, Other Jun 16 | 2021Novo to Expand Basal Insulin Titration App to EU and Asia; Novo Partners for Oral Protein Delivery; Closes $100M Series FPurchase Blast
$599
Posted in: Glucose Monitoring Jun 15 | 2021One Drop hires former Sanofi Head of Innovation and Diabetes portfolioPurchase Blast
$599
Posted in: GLP-1RA, Other Jun 10 | 2021Wegovy Added to Evernorth Obesity Program; STEP HFpEF DM Trial Observed; JDRF Issues RFA for CGM+Continuous Ketone Monitoring; One Drop Surpasses 25B Data PointsPurchase Blast
$599
Posted in: Basal Insulin, Other Jun 09 | 2021ViaCyte Closes $45M Series D Tranche; Oramed Randomizes 50% of Patients in Oral Insulin Trial; Dario Completes wayForward AcquistionPurchase Blast
$599
Posted in: GLP-1RA Jun 07 | 2021Wegovy Label Analysis; Novo Investor Event HighlightsPurchase Blast$599
Posted in: GLP-1RA Jun 04 | 2021Sema 2.4mg for Obesity Approved by FDA as "Wegovy"Purchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Jun 03 | 2021Lilly Debuts Connected Pen at ATTD; ATTD 2021 Key News (June 3)Purchase Blast$599
Posted in: Insulin Delivery, Other Jun 02 | 2021ATTD 2021 Key Press Releases (June 2)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i May 28 | 2021ADA 2021 Abstract and Session Titles AvailablePurchase Blast
$599
Posted in: Other May 27 | 2021Teplizumab Adcom: 10-7 Split Vote; Questions Raised on Teplizumab's ApprovabilityPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other May 27 | 2021Medtronic CY Q1 '21 Earnings Update; FDA Accepts IND for Lilly/Dicerna Cardiometabolic Asset; Dario Digital Therapeutics PublicationPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other May 26 | 2021InPen and Guardian 4 Sensor Receive CE Mark; Oramed Ph3 Oral Insulin Update; Adocia Files Patents for Obesity, NASH, and T2DMPurchase Blast
$599
Posted in: Other May 25 | 2021Provention Bio Teplizumab Adcom Pre-read Materials PostedPurchase Blast$599
Posted in: Glucagon, Other May 24 | 2021Xeris to Acquire Strongbridge; NGM Bio Discontinues NASH Program; BI Selects NASH Drug Candidate From DicernaPurchase Blast
$599
Posted in: Other May 20 | 2021SURPASS-4 Data Continue to Impress; Arecor and Lilly PartnershipPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
